DAFTAR PUSTAKA

Ahmed, A. I., & Lucas, J. D. (2020). Spinal cord injury: pathophysiology and strategies for regeneration. *Orthopaedics and Trauma*, 1–6. https://doi.org/10.1016/j.mporth.2020.06.003

Alizadeh, A., Dyck, S. M., & Karimi-Abdolrezaee, S. (2019). Traumatic Spinal Cord Injury: An Overview of Pathophysiology, Models and Acute Injury Mechanisms. *Frontiers in Neurology*, *10*(March), 1–25. https://doi.org/10.3389/fneur.2019.00282

Anwar, M. A., Al Shehabi, T. S., & Eid, A. H. (2016). Inflammogenesis of secondary spinal cord injury. *Frontiers in Cellular Neuroscience*, *10*(APR), 1–24. https://doi.org/10.3389/fncel.2016.00098

Bartholdi, D., Rubin, B. P., & Schwab, M. E. (1997). VEGF mRNA Induction Correlates With Changes in the Vascular Architecture Upon Spinal Cord Damage in the Rat. In *European Journal of Neuroscience* (Vol. 9).

Beattie, M. S., Hermann, G. E., Rogers, R. C., & Bresnahan, J. C. (2002). Cell death in models of spinal cord injury. *Progress in Brain Research*, *137*, 37–47. https://doi.org/10.1016/S0079-6123(02)37006-7

Bedreag, O. H., Rogobete, A. F., Sărăndan, M., Cradigati, A., Păpurică, M., Roşu, O. M., Dumbuleu, C. M., & Săndesc, D. (2014). Oxidative stress and antioxidant therapy in traumatic spinal cord injuries. *Romanian Journal of Anaesthesia and Intensive Care*, *21*(2), 123–129.

Cao, F., Yang, X. feng, Liu, W. guo, Hu, W. wei, Li, G., Zheng, X. jue, Shen, F., Zhao, X. qun, & Lv, S. ting. (2008). Elevation of neuron-specific enolase and S-100β protein level in experimental acute spinal cord injury. *Journal of Clinical Neuroscience*, *15*(5), 541–544. https://doi.org/10.1016/j.jocn.2007.05.014

Chen, C. L. H., Anqi, Q., & Yin, T. (2013). *The NeuroAiD II (MLC901) in Vascular Cognitive Impairment Study (NEURITES). 35*(suppl 1), 23–29. https://doi.org/10.1159/000346234

Cheriyan, T., Ryan, D. J., Weinreb, J. H., Cheriyan, J., Paul, J. C., Lafage, V., Kirsch, T., & Errico, T. J. (2014). Spinal cord injury models: A review. *Spinal Cord*, *52*(8), 588–595. https://doi.org/10.1038/sc.2014.91

Choi, J. S., Kim, H. Y., Cha, J. H., Choi, J. Y., Sang, I. P., Chang, H. J., Jeun, S. S., & Lee, M. Y. (2007). Upregulation of vascular endothelial growth factor receptors Flt-1 and Flk-1 following acute spinal cord contusion in rats. *Journal of Histochemistry and Cytochemistry*, *55*(8), 821–830. https://doi.org/10.1369/jhc.6A7139.2007

Crisler, R., Johnston, N. A., Sivula, C., & Budelsky, C. L. (2019). Functional anatomy and physiology. In *The Laboratory Rat* (pp. 91–132). Elsevier. https://doi.org/10.1016/B978-0-12-814338-4.00004-0

Donovan, W. H. (2007). Spinal cord injury - Past, present, and future. *Journal of Spinal Cord Medicine*, *30*(2), 85–100. https://doi.org/10.1080/10790268.2007.11753918

Doyle, K. P., Simon, R. P., & Stenzel-Poore, M. P. (2008). Mechanisms of ischemic brain damage. *Neuropharmacology*, *55*(3), 310–318. https://doi.org/10.1016/j.neuropharm.2008.01.005

Dumont, R. J., Okonkwo, D. O., Verma, S., Hurlbert, R. J., Boulos, P. T., Ellegala, D. B., & Dumont, A. S. (2001). Acute spinal cord injury, part I: Pathophysiologic mechanisms. *Clinical Neuropharmacology*, *24*(5), 254–264. https://doi.org/10.1097/00002826-200109000-00002

Fehlings, M. G., & Perrin, R. G. (2006). The timing of surgical intervention in the treatment of spinal cord injury: A systematic review of recent clinical evidence. *Spine*, *31*(11 SUPPL.), 28–35. https://doi.org/10.1097/01.brs.0000217973.11402.7f

Fehlings, M. G., Tetreault, L. A., Wilson, J. R., Kwon, B. K., Burns, A. S., Martin, A. R., Hawryluk, G., & Harrop, J. S. (2017). A Clinical Practice Guideline for the Management of Acute Spinal Cord Injury: Introduction, Rationale, and Scope. *Global Spine Journal*, *7*(3_supplement), 84S-94S. https://doi.org/10.1177/2192568217703387

Fehlings, M. G., Vaccaro, A., Wilson, J. R., Singh, A., Cadotte, D. W., Harrop, J. S., Aarabi, B., Shaffrey, C., Dvorak, M., Fisher, C., Arnold, P., Massicotte, E. M., Lewis, S., & Rampersaud, R. (2012). Early versus delayed decompression for traumatic cervical spinal cord injury: Results of the surgical timing in acute spinal cord injury study (STASCIS). *PLoS ONE*, *7*(2). https://doi.org/10.1371/journal.pone.0032037

Forgione, N., Karadimas, S. K., Foltz, W. D., Satkunendrarajah, K., Lip, A., & Fehlings, M. G. (2014). Bilateral contusion-compression model of incomplete traumatic cervical spinal cord injury. *Journal of Neurotrauma*, *31*(21), 1776–1788. https://doi.org/10.1089/neu.2014.3388

Fouad, K., Ng, C., & Basso, D. M. (2020). Behavioral testing in animal models of spinal cord injury. *Experimental Neurology*, *333*(July). https://doi.org/10.1016/j.expneurol.2020.113410

Gandin, C., Widmann, C., Lazdunski, M., & Heurteaux, C. (2016). MLC901 Favors Angiogenesis and Associated Recovery after Ischemic Stroke in Mice. *Cerebrovascular Diseases*, *42*(1–2), 139–154. https://doi.org/10.1159/000444810

Haque, A., Capone, M., Matzelle, D., Cox, A., & Banik, N. L. (2017). Targeting Enolase in Reducing Secondary Damage in Acute Spinal Cord Injury in Rats. *Neurochemical Research*, *42*(10), 2777–2787. https://doi.org/10.1007/s11064-017-2291-z

Haque, A., Polcyn, R., Matzelle, D., & Banik, N. L. (2018). New insights into the role of neuron-specific enolase in neuro-inflammation, neurodegeneration, and neuroprotection. *Brain Sciences*, *8*(2). https://doi.org/10.3390/brainsci8020033

Haque, A., Ray, S. K., Cox, A., & Banik, N. L. (2016a). Neuron specific enolase: a promising therapeutic target in acute spinal cord injury. *Metabolic Brain Disease*, *31*(3), 487–495. https://doi.org/10.1007/s11011-016-9801-6

Haque, A., Ray, S. K., Cox, A., & Banik, N. L. (2016b). Neuron specific enolase: a promising therapeutic target in acute spinal cord injury. In *Metabolic Brain Disease* (Vol. 31, Issue 3, pp. 487–495). Springer New York LLC. https://doi.org/10.1007/s11011-016-9801-6

Hausmann, O. N. (2003). Post-traumatic inflammation following spinal cord injury. *Spinal Cord*, *41*(7), 369–378. https://doi.org/10.1038/sj.sc.3101483

Hawryluk, G. W. J., Hiroaki Nakashima, & Fehlings, M. G. (2017). Pathophysiology and Treatment of Spinal Cord Injury. In *Youmans and Winn Neurological Surgery, 4-Volume Set* (seven, pp. 2292–2307). Elsevier.

Herrera, J. J., Nesic, O., & Narayana, P. A. (2009). Reduced Vascular Endothelial Growth Factor Expression in Contusive Spinal Cord Injury. *J Neurotrauma*.

Heurteaux, C., Gandin, C., Borsotto, M., Widmann, C., Brau, F., Lhuillier, M., Onteniente, B., & Lazdunski, M. (2010). Neuroprotective and neuroproliferative activities of NeuroAid (MLC601, MLC901), a Chinese medicine, in vitro and in vivo. *Neuropharmacology*, *58*(7), 987–1001. https://doi.org/10.1016/j.neuropharm.2010.01.001

Heurteaux, C., Widmann, C., Moha Ou Maati, H., Quintard, H., Gandin, C., Borsotto, M., Veyssiere, J., Onteniente, B., & Lazdunski, M. (2013). NeuroAiD: Properties for neuroprotection and neurorepair. *Cerebrovascular Diseases*, *35*(SUPPL.1), 1–7. https://doi.org/10.1159/000346228

Jia, Z., Zhu, H., Li, J., Wang, X., Misra, H., & Li, Y. (2012). Oxidative stress in spinal cord injury and antioxidant-based intervention. *Spinal Cord*, *50*(4), 264–274. https://doi.org/10.1038/sc.2011.111

Kigerl, K. A., Gensel, J. C., Ankeny, D. P., Alexander, J. K., Donnelly, D. J., & Popovich, P. G. (2009). Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. *Journal of Neuroscience*, *29*(43), 13435–13444. https://doi.org/10.1523/JNEUROSCI.3257-09.2009

Kirshblum, S. C., Waring, W., Biering-Sorensen, F., Burns, S. P., Johansen, M., Schmidt-Read, M., Donovan, W., Graves, D., Jha, A., Jones, L., Mulcahey, M. J., & Krassioukov, A. (2011). Reference for the 2011 revision of the International Standards for Neurological Classification of Spinal Cord Injury. *Journal of Spinal Cord Medicine*, *34*(6), 547–554. https://doi.org/10.1179/107902611X13186000420242

Kong, X., & Gao, J. (2017). Macrophage polarization: a key event in the secondary phase of acute spinal cord injury. *Journal of Cellular and Molecular Medicine*, *21*(5), 941–954. https://doi.org/10.1111/jcmm.13034

Krueger, H., Noonan, V. K., Trenaman, L. M., Joshi, P., & Rivers, C. S. (2013). The economic burden of traumatic spinal cord injury in Canada. *Chronic Diseases and Injuries in Canada*, *33*(3), 113–122.

Kumar, R., Htwe, O., Baharudin, A., Ariffin, M. H., Abdul Rhani, S., Ibrahim, K., Rustam, A., & Gan, R. (2016). Spinal Cord Injury—Assessing Tolerability and Use of Combined Rehabilitation and NeuroAiD (SATURN Study): Protocol of An Exploratory Study In Assessing the Safety and Efficacy of NeuroAiD Amongst People Who Sustain Severe Spinal Cord Injury. *JMIR Research Protocols*, *5*(4), e230. https://doi.org/10.2196/resprot.6275

Kwon, B. K., Tetzlaff, W., Grauer, J. N., Beiner, J., & Vaccaro, A. R. (2004). Pathophysiology and pharmacologic treatment of acute spinal cord injury. *Spine Journal*, *4*(4), 451–464. https://doi.org/10.1016/j.spinee.2003.07.007

Lange, C., Storkebaum, E., de Almodóvar, C. R., Dewerchin, M., & Carmeliet, P. (2016). Vascular endothelial growth factor: A neurovascular target in neurological diseases. In *Nature Reviews Neurology* (Vol. 12, Issue 8, pp. 439–454). Nature Publishing Group. https://doi.org/10.1038/nrneurol.2016.88

Li, J., Chen, S., Zhao, Z., Luo, Y., Hou, Y., Li, H., He, L., Zhou, L., & Wu, W. (2017). Effect of VEGF on inflammatory regulation, neural survival, and functional improvement in rats following a complete spinal cord transection. *Frontiers in Cellular Neuroscience*, *11*(November). https://doi.org/10.3389/fncel.2017.00381

Long, H. Q., Li, G. S., Cheng, X., Xu, J. H., & Li, F. B. (2015). Role of hypoxia-induced VEGF in blood-spinal cord barrier disruption in chronic spinal cord injury. In *Chinese Journal of Traumatology - English Edition* (Vol. 18, Issue 5, pp. 293–295). Elsevier B.V. https://doi.org/10.1016/j.cjtee.2015.08.004

Lőw, P., Molnár, K., & Kriska, G. (2016). Dissection of the Rat (Rattus norvegicus). In *Atlas of Animal Anatomy and Histology* (pp. 325–399). Springer International Publishing. https://doi.org/10.1007/978-3-319-25172-1_12

Loy, D. N., Sroufe, A. E., Pelt, J. L., Burke, D. A., Cao, Q. L., Talbott, J. F., & Whittemore, S. R. (2005). Serum biomarkers for experimental acute spinal cord injury: Rapid elevation of neuron-specific enolase and S-100β. *Neurosurgery*, *56*(2), 391–396. https://doi.org/10.1227/01.NEU.0000148906.83616.D2

Malhotra, S. L. C. M., Bhatoe, B. H. S., & Sudambrekar, C. S. M. (2010). Spinal cord injuries. *Medical Journal Armed Forces India*, *66*(4), 325–328. https://doi.org/10.1016/s0377-1237(10)80009-7

Mataliotakis, G. I., & Tsirikos, A. I. (2016). Spinal cord trauma: pathophysiology, classification of spinal cord injury syndromes, treatment principles and controversies. *Orthopaedics and Trauma*, *30*(5), 440–449. https://doi.org/10.1016/j.mporth.2016.07.006

Mattson, M. P. (2019). Excitotoxicity. *Stress: Physiology, Biochemistry, and Pathology*, 125–134. https://doi.org/10.1016/b978-0-12-813146-6.00011-4

McDonough, A., Monterrubio, A., Ariza, J., & Martínez-Cerdeño, V. (2015). Calibrated forceps model of spinal cord compression injury. *Journal of Visualized Experiments*, *2015*(98), 1–6. https://doi.org/10.3791/52318

Moha Ou Maati, H., Borsotto, M., Chatelain, F., Widmann, C., Lazdunski, M., & Heurteaux, C. (2012). Activation of ATP-sensitive potassium channels as an element of the neuroprotective effects of the Traditional Chinese Medicine MLC901 against oxygen glucose deprivation. *Neuropharmacology*, *63*(4), 692–700. https://doi.org/10.1016/j.neuropharm.2012.05.035

Muhammad Faris. (2020). *Pengaruh Pemberian ACTH4-10PRO8GLY9PRO10 Terhadap Mediator Proinflamasi TLR, NF-Kb, IL-8, TNF-α, DAN Neutrofil pada Jaringan Spinal Cord yang Mengalami Cedera Kompresi Akut (Studi Eksperimental pada Tikus Sprague-Dawley Model Spinal Cord Injury)* .

Ning, G. Z., Wu, Q., Li, Y. L., & Feng, S. Q. (2012). Epidemiology of traumatic spinal cord injury in Asia: A systematic review. *Journal of Spinal Cord Medicine*, *35*(4), 229–239. https://doi.org/10.1179/2045772312Y.0000000021

Pakdaman, H., Harandi, A. A., Gharagozli, K., Abbasi, M., Ghaffarpour, M., Ashrafi, F., Kasmaei, H. D., & Harandi, A. A. (2017). MLC601 in vascular dementia: An efficacy and safety pilot study. *Neuropsychiatric Disease and Treatment*, *13*, 2551–2557. https://doi.org/10.2147/NDT.S145047

Park, E., Velumian, A. A., & Fehlings, M. G. (2004). The role of excitotoxicity in secondary mechanisms of spinal cord injury: A review with an emphasis on the implications for white matter degeneration. *Journal of Neurotrauma*, *21*(6), 754–774. https://doi.org/10.1089/0897715041269641

Patek, M., & Stewart, M. (2020). Spinal cord injury. *Anaesthesia and Intensive Care Medicine*, 1–6. https://doi.org/10.1016/j.mpaic.2020.05.006

Paterniti, I., Esposito, E., & Cuzzocrea, S. (2016). Role of the Neuroinflammation in the Degree of Spinal Cord Injury: New Therapeutic Strategies. *Recovery of Motor Function Following Spinal Cord Injury*. https://doi.org/10.5772/63222

Polcyn, R., Capone, M., Hossain, A., Matzelle, D., Banik, N. L., Haque, A., & Haque, A. (2017). Enolase and Acute Spinal Cord Injury. *Journal of Clinical & Cellular Immunology*, *08*(06), 8–10. https://doi.org/10.4172/2155-9899.1000536

Poon, P. C., Gupta, D., Shoichet, M. S., & Tator, C. H. (2007). Clip compression model is useful for thoracic spinal cord injuries: Histologic and functional correlates. *Spine*, *32*(25), 2853–2859. https://doi.org/10.1097/BRS.0b013e31815b7e6b

Qin, Z., Chen, H., Bin, M., Tiansi, T., & Huilin, Y. (2014). Changes in autophagy proteins in a rat model of spinal cord injury. *Chinese Journal of Traumatology - English Edition*, *17*(4), 193–197. https://doi.org/10.3760/cma.j.issn.1008-1275.2014.04.002

Quintard, H., Borsotto, M., Veyssiere, J., Gandin, C., Labbal, F., Widmann, C., Lazdunski, M., & Heurteaux, C. (2011). MLC901, a Traditional Chinese Medicine

protects the brain against global ischemia. *Neuropharmacology*, *61*(4), 622–631. https://doi.org/10.1016/j.neuropharm.2011.05.003

Quintard, H., Lorivel, T., Gandin, C., Lazdunski, M., & Heurteaux, C. (2014a). MLC901, a Traditional Chinese Medicine induces neuroprotective and neuroregenerative benefits after traumatic brain injury in rats. *Neuroscience*, *277*, 72–86. https://doi.org/10.1016/j.neuroscience.2014.06.047

Quintard, H., Lorivel, T., Gandin, C., Lazdunski, M., & Heurteaux, C. (2014b). MLC901, a Traditional Chinese Medicine induces neuroprotective and neuroregenerative benefits after traumatic brain injury in rats. *Neuroscience*, *277*, 72–86. https://doi.org/10.1016/j.neuroscience.2014.06.047

Raineteau, O., & Schwab, M. E. (2001). Plasticity of motor systems after incomplete spinal cord injury. *Nature Reviews Neuroscience*, *2*(4), 263–273. https://doi.org/10.1038/35067570

Ranuh, I. G. M. A. R., Sari, G. M., Utomo, B., Suroto, N. S., & Fauzi, A. al. (2021). Systematic Review and Meta-Analysis of the Efficacy of MLC901 (NeuroAiD IITM) for Acute Ischemic Brain Injury in Animal Models. In *Journal of Evidence-Based Integrative Medicine* (Vol. 26). SAGE Publications Ltd. https://doi.org/10.1177/2515690X211039219

Rodrigues, L. F., Moura-Neto, V., & e Spohr, T. C. L. de S. (2018). Biomarkers in Spinal Cord Injury: from Prognosis to Treatment. *Molecular Neurobiology*, *55*(8), 6436–6448. https://doi.org/10.1007/s12035-017-0858-y

Rosyidi, R. M., Priyanto, B., Islam, A. A., Hatta, M., Bukhari, A., Prihastomo, K. T., Nasution, R. A., Rozikin, & Prihatina, L. M. (2020). Role of MLC901 in increasing neurogenesis in rats with traumatic brain injury. *Annals of Medicine and Surgery*, *60*, 36–40. https://doi.org/10.1016/j.amsu.2020.10.013

Rowland, J. W., Hawryluk, G. W. J., Kwon, B., & Fehlings, M. G. (2008). Current status of acute spinal cord injury pathophysiology and emerging therapies: Promise on the horizon. *Neurosurgical Focus*, *25*(5), 1–3. https://doi.org/10.3171/FOC.2008.25.11.E2

Rust, R., & Kaiser, J. (2017). Insights into the dual role of inflammation after spinal cord injury. *Journal of Neuroscience*, *37*(18), 4658–4660. https://doi.org/10.1523/JNEUROSCI.0498-17.2017

Scheff, S. W., Saucier, D. A., & Cain, M. E. (2002). A statistical method for analyzing rating scale data: The BBB locomotor score. *Journal of Neurotrauma*, *19*(10), 1251–1260. https://doi.org/10.1089/08977150260338038

Sengul, G., & Watson, C. (2012). Spinal Cord. In *The Mouse Nervous System* (pp. 424–458). Elsevier Inc. https://doi.org/10.1016/B978-0-12-369497-3.10013-5

Shaik, A. J., Reddy, K., Mohammed, N., Tandra, S. R., Rukmini mridula kandadai, & Baba KSS, S. (2019). Neuron specific enolase as a marker of seizure related neuronal injury. *Neurochemistry International*, *131*. https://doi.org/10.1016/j.neuint.2019.104509

Sharif-Alhoseini, M., & Rahimi-Movaghar, V. (2014). Animal Models in Traumatic Spinal Cord Injury. *Topics in Paraplegia*. https://doi.org/10.5772/57189

Silva, N. A., Sousa, N., Reis, R. L., & Salgado, A. J. (2014). From basics to clinical: A comprehensive review on spinal cord injury. *Progress in Neurobiology*, *114*, 25–57. https://doi.org/10.1016/j.pneurobio.2013.11.002

Sköld, M., Cullheim, S., Hammarberg, H., Piehl, F., Suneson, A., Lake, S., Sjögren, A., Walum, E., & Risling, M. (2000). Induction of VEGF and VEGF receptors in the spinal cord after mechanical spinal injury and prostaglandin administration.

European Journal of Neuroscience, *12*(10). https://doi.org/10.1046/j.1460-9568.2000.00263.x

Storkebaum, E., Lambrechts, D., & Carmeliet, P. (2004). VEGF: Once regarded as a specific angiogenic factor, now implicated in neuroprotection. *BioEssays*, *26*(9), 943–954. https://doi.org/10.1002/bies.20092

Suwanwela, N. C., Chen, C. L. H., Lee, C. F., Young, S. H., Tay, S. S., Umapathi, T., Lao, A. Y., Gan, H. H., Baroque, A. C., Navarro, J. C., Chang, H. M., Advincula, J. M., Muengtaweepongsa, S., Chan, B. P. L., Chua, C. L., Wijekoon, N., De Silva, H. A., Hiyadan, J. H. B., Wong, K. S. L., … Ranawake, U. (2018). Effect of Combined Treatment with MLC601 (NeuroAiD TM) and Rehabilitation on Post-Stroke Recovery: The CHIMES and CHIMES-E Studies. *Cerebrovascular Diseases*, *46*(1–2), 82–88. https://doi.org/10.1159/000492625

Taghva, A., Hoh, D. J., & Lauryssen, C. L. (2012). Advances in the management of spinal cord and spinal column injuries. In *Handbook of Clinical Neurology* (1st ed., Vol. 109). Elsevier B.V. https://doi.org/10.1016/B978-0-444-52137-8.00007-3

Tator, C. H., & Poon, P. (2009). Acute Clip Impact-Compression Model. In *Animal Models of Acute Neurological Injuries* (pp. 449–460). Humana press.

Theadom, A., Barker-Collo, S., Jones, K. M., Parmar, P., Bhattacharjee, R., & Feigin, V. L. (2018). MLC901 (NeuroAiD II^{TM}) for cognition after traumatic brain injury: a pilot randomized clinical trial. *European Journal of Neurology*, *25*(8), 1055-e82. https://doi.org/10.1111/ene.13653

Walker, M. J., & Xu, X. M. (2018). Pleiotropic Role of VEGF and Its Application for Traumatic Spinal Cord Injury. In *Annals of Spine Research* (Vol. 1, Issue 1).

Wang, H., Wang, Y., Li, D., Liu, Z., Zhao, Z., Han, D., Yuan, Y., Bi, J., & Mei, X. (2015). VEGF inhibits the inflammation in spinal cord injury through activation of autophagy. *Biochemical and Biophysical Research Communications*, *464*(2), 453–458. https://doi.org/10.1016/j.bbrc.2015.06.146

Widmann, C., Gandin, C., Lazdunski, M., & Heurteaux, C. (2018). The Traditional Chinese Medicine MLC901 inhibits inflammation processes after focal cerebral ischemia. *Scientific Reports*, *March*, 1–15. https://doi.org/10.1038/s41598-018-36138-0

Wilson, J. R., & Fehlings, M. G. (2011). Emerging Approaches to the Surgical Management of Acute Traumatic Spinal Cord Injury. *Neurotherapeutics*, *8*(2), 187–194. https://doi.org/10.1007/s13311-011-0027-3

Xm, X., & Mj, W. (2018). *Annals of Spine Research Pleiotropic Role of VEGF and Its Application for Traumatic*. *1*(1).

Yokobori, S., Zhang, Z., Moghieb, A., Mondello, S., Gajavelli, S., Dietrich, W. D., Bramlett, H., Hayes, R. L., Wang, M., Wang, K. K. W., & Bullock, M. R. (2015). Acute diagnostic biomarkers for spinal cord injury: Review of the literature and preliminary research report. In *World Neurosurgery* (Vol. 83, Issue 5, pp. 867–878). Elsevier Inc. https://doi.org/10.1016/j.wneu.2013.03.012

Zhang, B., Bailey, W. M., McVicar, A. L., & Gensel, J. C. (2016). Age increases reactive oxygen species production in macrophages and potentiates oxidative damage after spinal cord injury. *Neurobiology of Aging*, *47*, 157–167. https://doi.org/10.1016/j.neurobiolaging.2016.07.029

LAMPIRAN

Lampiran 1

Persetujuan Etik

KEMENTERIAN PENDIDIKAN DAN KEBUDAYAAN
UNIVERSITAS HASANUDDIN FAKULTAS KEDOKTERAN
KOMITE ETIK PENELITIAN KESEHATAN
RSPTN UNIVERSITAS HASANUDDIN
RSUP Dr. WAHIDIN SUDIROHUSODO MAKASSAR
Sekretariat : Lantai 2 Gedung Laboratorium Terpadu
JL.PERINTIS KEMERDEKAAN KAMPUS TAMALANREA KM.10 MAKASSAR 90245.
Contact Person: dr. Agussalim Bukhari,,MMed,PhD, SpGK. TELP. 081241850858, 0411 5780903, Fax : 0411 581431

REKOMENDASI PERSETUJUAN ETIK
Nomor : 599/UN4.6.4.5.31/ PP36/ 2020
Tanggal: 29 September 2020

Dengan ini Menyatakan bahwa Protokol dan Dokumen yang Berhubungan Dengan Protokol berikut ini telah mendapatkan Persetujuan Etik :

No Protokol	UH20090466	No Sponsor Protokol	
Peneliti Utama	**dr. Wahyudi, SpBS**	Sponsor	
Judul Peneliti	Pengaruh Pemberian MLC901 Terhadap Ekspresi mRNA Gen Vascular Endothelial Growth Factor (VEGF), Kadar Neuron Spesific Enolase (NSE), Histopatologi dan Fungsi Lokomotor Pada Animal Model Cedera Korda Spinalis		
No Versi Protokol	**1**	Tanggal Versi	**5 September 2020**
No Versi PSP		Tanggal Versi	
Tempat Penelitian	**Laboratorium Animal Bagian Mikrobiologi dan Biologi Molekular Fakultas Kedokteran Universitas Hasanuddin Makassar**		
Jenis Review	[ ] Exempted [x] Expedited [ ] Fullboard Tanggal	Masa Berlaku **29 September 2020** sampai **29 September 2021**	Frekuensi review lanjutan
Ketua Komisi Etik Penelitian Kesehatan FKUH	Nama **Prof.Dr.dr. Suryani As'ad, M.Sc.,Sp.GK (K)**	Tanda tangan	
Sekretaris Komisi Etik Penelitian Kesehatan FKUH	Nama **dr. Agussalim Bukhari, M.Med.,Ph.D.,Sp.GK (K)**	Tanda tangan	

Kewajiban Peneliti Utama:
- Menyerahkan Amandemen Protokol untuk persetujuan sebelum di implementasikan
- Menyerahkan Laporan SAE ke Komisi Etik dalam 24 Jam dan dilengkapi dalam 7 hari dan Lapor SUSAR dalam 72 jam setelah Peneliti Utama menerima laporan
- Menyerahkan Laporan Kemajuan (progress report) setiap 6 bulan untuk penelitian resiko tinggi dan setiap setahun untuk penelitian resiko rendah
- Menyerahkan laporan akhir setelah Penelitian berakhir
- Melaporkan penyimpangan dari prokol yang disetujui (protocol deviation / violation)
- Mematuhi semua peraturan yang ditentukan

Lampiran 2

Foto Kegiatan :

1. Aklimatisasi tikus *Sprague Dawley* dan tempat pemeliharaan tikus

2. Laminektomi dan *Clip Compression*






3. Alat, obat, sonde dan *Collecting* sampel darah serta proses pewarnaan jaringan

Lampiran 3

Hasil Pengelolaan Data Menggunakan SPSS

	Perlakuan1	Mean	Std. Deviation	N
VEGF Elisa Sebelum Perlakuan	Kontrol	50.3364	16.24244	5
	MLC901	46.9642	14.91583	5
	Total	48.6503	14.80850	10
VEGF Elisa 2 Jam setelah perlakuan	Kontrol	129.5872	7.45872	5
	MLC901	140.1210	16.32136	5
	Total	134.8541	13.18872	10
VEGF Elisa 3 Jam setelah perlakuan	Kontrol	185.4526	15.70492	5
	MLC901	117.0442	16.53450	5
	Total	151.2484	39.12858	10
VEGF Elisa 7 Hari setelah Perlakuan	Kontrol	228.7082	13.94224	5
	MLC901	98.2120	11.38366	5
	Total	163.4601	69.81646	10
VEGF Elisa 14 Hari setelah Perlakuan	Kontrol	245.5216	15.64717	5
	MLC901	60.3934	7.87271	5
	Total	152.9575	98.26742	10

				95% Confidence Interval	
Perlakuan1	Time	Mean	Std. Error	Lower Bound	Upper Bound
Kontrol	1	50.336	6.974	34.255	66.417
	2	129.587	5.675	116.501	142.673
	3	185.453	7.211	168.823	202.082
	4	228.708	5.692	215.583	241.834
	5	245.522	5.539	232.748	258.295
MLC901	1	46.964	6.974	30.883	63.045
	2	140.121	5.675	127.035	153.207
	3	117.044	7.211	100.415	133.674
	4	98.212	5.692	85.087	111.337
	5	60.393	5.539	47.620	73.167

Waktu	Pemberian MLC901	VEGF ELISA		Perbedaan Rerata	P
		Mean	Std. Deviation		
Sebelum Perlakuan	(+)	46,97	14,91	-3,65	0,74
	(-)	50,34	16,24		
2 jam setelah perlakuan	(+)	140,12	16,32	10.53	0,23
	(-)	129,59	7,46		
3 jam setelah perlakuan	(+)	117,04	16,53	-68,41	0,00
	(-)	185.45	15,70		
7 hari setelah	(+)	98,21	11,38	-130.5	0,00

perlakuan	(-)	228,71	13,94		
14 hari setelah perlakuan	(+)	60,40	7,87	-91,56	0,00
	(-)	152,96	15,64		

	Perlakuan1	Mean	Std. Deviation	N
VEGF mRNA sebelum perlakuan	Kontrol	6.1710	.50469	5
	MLC901	5.8862	.61165	5
	Total	6.0286	.54956	10
VEGF mRNA 2 jam setelah perlakuan	Kontrol	9.8554	.56702	5
	MLC901	10.2754	.53602	5
	Total	10.0654	.56532	10
VEGF mRNA 3 jam setelah peralkuan	Kontrol	11.6692	.58271	5
	MLC901	8.8896	.47439	5
	Total	10.2794	1.54825	10
VEGF mRNA 7 hrasetelah Perlakuan	Kontrol	14.0714	.49945	5
	MLC901	7.8110	.45660	5
	Total	10.9412	3.33022	10
VEGF mRNA 14 hari setelah perlakuan	Kontrol	14.4710	.65116	5
	MLC901	7.2564	.52611	5
	Total	10.8637	3.84317	10

				95% Confidence Interval	
Perlakuan1	Time	Mean	Std. Error	Lower Bound	Upper Bound
Kontrol	1	6.171	.251	5.593	6.749
	2	9.855	.247	9.286	10.424
	3	11.669	.238	11.121	12.217
	4	14.071	.214	13.578	14.565
	5	14.471	.265	13.861	15.081
MLC901	1	5.886	.251	5.308	6.464
	2	10.275	.247	9.706	10.844
	3	8.890	.238	8.342	9.438
	4	7.811	.214	7.318	8.304
	5	7.256	.265	6.646	7.867

Waktu	Pemberian MLC901	mRNA gen VEGF		Perbedaan Rerata	P
		Mean	Std. Deviation		
Sebelum Perlakuan	(+)	5,89	0,62	-0,28	0,45
	(-)	6,17	0,50		
2 jam setelah perlakuan	(+)	10,28	0,54	0,42	0,26
	(-)	9,86	0,56		
3 jam setelah perlakuan	(+)	8,89	0,47	-2,78	0,00
	(-)	11,67	0,58		
7 hari setelah perlakuan	(+)	7,81	0,45	-6,26	0,00
	(-)	14,07	0,50		
14 hari setelah perlakuan	(+)	7,26	0,53	-7,21	0,00
	(-)	14,47	0,65		

	Perlakuan1	Mean	Std. Deviation	N
NSE sebelum perlakuan	Kontrol	4.2122	3.29671	5
	MLC901	4.8720	2.62162	5
	Total	4.5421	2.82947	10
NSE 2 jam setelah perlakuan	Kontrol	26.7870	2.87325	5
	MLC901	26.3254	3.04647	5
	Total	26.5562	2.80236	10
NSE 3 Jam setelah perlakuan	Kontrol	35.3152	3.44603	5
	MLC901	21.1920	2.06153	5
	Total	28.2536	7.91034	10
NSE 7 hari setelah perlakuan	Kontrol	45.0638	4.02061	5
	MLC901	16.6306	1.58196	5
	Total	30.8472	15.25993	10
NSE 14 hari setelah perlakuan	Kontrol	48.5542	3.56725	5
	MLC901	11.2714	2.56085	5
	Total	29.9128	19.86664	10

Perlakuan1	Time	Mean	Std. Error	95% Confidence Interval	
				Lower Bound	Upper Bound
Kontrol	1	4.212	1.332	1.141	7.284
	2	26.787	1.324	23.733	29.841
	3	35.315	1.270	32.387	38.243
	4	45.064	1.366	41.913	48.215
	5	48.554	1.389	45.352	51.756
MLC901	1	4.872	1.332	1.800	7.944
	2	26.325	1.324	23.272	29.379
	3	21.192	1.270	18.264	24.120
	4	16.631	1.366	13.480	19.781
	5	11.271	1.389	8.069	14.474

Waktu	Pemberian MLC901	NSE ELISA		Perbedaan Rerata	P
		Mean	Std. Deviation		
Sebelum Perlakuan	(+)	4,87	2,62	0,66	0,74
	(-)	4,21	3,30		
2 jam setelah perlakuan	(+)	26,33	3,04	-0,45	0,81
	(-)	26,78	2,87		
3 jam setelah perlakuan	(+)	21,20	2,06	-14,11	0,00
	(-)	35,31	3,45		
7 hari setelah perlakuan	(+)	16,63	1,58	-28,43	0,00
	(-)	45,06	4,02		
14 hari setelah perlakuan	(+)	11,27	2,56	-37,28	0,00
	(-)	48,55	3,57		

		Persentase kerusakan hari ke-14	VEGF mRNA 14 hari setelah perlakuan
Persentase kerusakan hari ke-14	Pearson Correlation	1	.909**
	Sig. (2-tailed)		.000
	N	10	10
VEGF mRNA 14 hari setelah perlakuan	Pearson Correlation	.909**	1
	Sig. (2-tailed)	.000	
	N	10	10

**. Correlation is significant at the 0.01 level (2-tailed).

		Persentase kerusakan hari ke-14	NSE 14 hari setelah perlakuan
Persentase kerusakan hari ke-14	Pearson Correlation	1	.935**
	Sig. (2-tailed)		.000
	N	10	10
NSE 14 hari setelah perlakuan	Pearson Correlation	.935**	1
	Sig. (2-tailed)	.000	
	N	10	10

**. Correlation is significant at the 0.01 level (2-tailed).

		VEGF Elisa 14 Hari setelah Perlakuan	Persentase kerusakan hari ke-14
VEGF Elisa 14 Hari setelah Perlakuan	Pearson Correlation	1	.924**
	Sig. (2-tailed)		.000
	N	10	10
Persentase kerusakan hari ke-14	Pearson Correlation	.924**	1
	Sig. (2-tailed)	.000	
	N	10	10

**. Correlation is significant at the 0.01 level (2-tailed).

		Skor BBB 14 hari setelah perlakuan	NSE 14 hari setelah perlakuan
Skor BBB 14 hari setelah perlakuan	Pearson Correlation	1	-.956**
	Sig. (2-tailed)		.000
	N	10	10
NSE 14 hari setelah perlakuan	Pearson Correlation	-.956**	1
	Sig. (2-tailed)	.000	
	N	10	10

**. Correlation is significant at the 0.01 level (2-tailed).

		Skor BBB 14 hari setelah perlakuan	VEGF mRNA 14 hari setelah perlakuan
Skor BBB 14 hari setelah perlakuan	Pearson Correlation	1	-.941**
	Sig. (2-tailed)		.000
	N	10	10
VEGF mRNA 14 hari setelah perlakuan	Pearson Correlation	-.941**	1
	Sig. (2-tailed)	.000	
	N	10	10

**. Correlation is significant at the 0.01 level (2-tailed).